No second PI for 10x against NanoString, UPC rules

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

No second PI for 10x against NanoString, UPC rules

Munich.jpg
Munich

Judge Matthias Zigann said the panel wasn’t convinced that NanoString had infringed the 10x Genomics patent

The Unified Patent Court refused to grant a second preliminary injunction for 10x Genomics against rival biotech company NanoString in Munich today, October 10.

Presiding judge Matthias Zigann said the panel was unconvinced that NanoString had infringed 10x’s patent.

The judge said the panel’s findings on infringement and validity were not prejudicial on the main proceedings.

10x won the first full PI hearing in the court’s history last month over a separate but related patent. That ruling meant NanoString cannot sell its allegedly infringing products in 17 European countries while proceedings are ongoing.

The lawsuit concerns NanoString’s CosMx Spatial Molecular Imager device and CosMx reagents for RNA detection.

10x claimed NanoString infringed patents related to Xenium, the company’s own RNA analysis tool that it launched in December 2022.

There is parallel litigation between the parties at the US District Court for the District of Delaware, where 10x has also filed two infringement lawsuits.

Trials have been scheduled in Delaware in November 2023 and September 2024.

NanoString has argued that 10x’s technology was originally developed at Harvard University with grant funding from the US National Institutes of Health, with the intention it would be made widely available via licensing.

Harvard exclusively licensed the technology to ReadCoor, which was acquired by 10x in 2020.

“In contrast with the promises made in the grant application, 10x is now using the acquired ReadCoor patents in lawsuits designed to reduce the scientific community’s access to innovative technologies intended for broad access,” NanoString has claimed.

Germany’s Federal Patent Court has also issued a preliminary opinion in which it found the claims of one of 10x’s key patents to be valid. An oral hearing has been scheduled for May 2024.

The Munich Regional Court, meanwhile, granted an injunction in favour of 10x in May this year. NanoString has appealed against that ruling to the Higher Regional Court.

10x may yet appeal the latest UPC ruling. The UPC has yet to schedule a date for a trial on the merits of the case.

more from across site and SHARED ros bottom lb

More from across our site

The firm has taken the bold step of ditching the billable hour as its default pricing mechanism – watch now as rivals follow suit
The IP services provider is targeting further expansion as cost and efficiency pressures push law firms and in-house teams to rethink how they manage global portfolios
Two experienced UPC practitioners join the UK IP boutique’s growing German operation, with further recruitment planned as the firm expands in Europe
The Australian IP firm is taking on bigger rivals in Southeast Asia, betting that agility and transparent pricing can help it stand out
The firm has brought in former Weil IP leaders Doug Lumish and Jeff Homrig as it looks to deepen its patent, trade secrets and ITC bench
Bird & Bird helps GSK score a major injunction as the battle to become the UPC’s busiest division tightens, and overall filings reach a new monthly high
CEO Annette Bach explains how the Danish IP consultancy plans to build on its 65% profit growth while keeping external investment off the table for now
Belgian attorneys have revived fax systems to protect clients’ filing rights, while uncertainty over exposed patent data has left firms struggling to answer questions about the breach
In his first interview since leaving Weil Gotshal & Manges, Chris Henry explains why he returned to Latham and how he plans to bolster its tech disputes offering
As GTA VI underlines the extraordinary value of gaming franchises, lawyers at Clifford Chance say investors need to know the IP behind their next deal can deliver the growth they are paying for
Gift this article